Skip to content ↓



Download RSS feed: News Articles / In the Media

Displaying 1 - 15 of 40 news clips related to this topic.


CNBC reporter Charlie Wood features tProf. Connor Coley's work developing a new system that could be used to help automate molecule manufacturing. “It tries to understand, based on those patterns, what kind of transformations should work for new molecules it’s never seen before,” says Coley.

The Wall Street Journal

The Association for the Advancement of Artificial Intelligence has awarded Prof. Regina Barzilay a $1 million prize for her work advancing the use of AI in medicine, reports John McCormick for The Wall Street Journal. "Regina is brilliant, has very high standards, and is committed to helping others,” says Prof. James Collins. “And I think her experience with—her personal experience with cancer—has motivated her to apply her intellectual talents to using AI to advance health care.”

Associated Press

The AP highlights how Prof. Regina Barzilay has been named the inaugural winner of a new award given by the Association for the Advancement of Artificial Intelligence for her work “using computer science to detect cancer and discover new drugs has won a new $1 million award for artificial intelligence.”


Prof. Regina Barzilay has been named the inaugural recipient of the Squirrel AI Award for Artificial Intelligence to Benefit Humanity for her work developing new AI techniques to help improve health care, reports Rebecca Robbins for STAT. Robbins writes that Barzilay is focused on turning the “abundance of research on AI in health care into tools that can improve care.”


STAT reporter Kate Sheridan spotlights MIT startup Lyra Therapeutics, which is developing a long-acting treatment for chronic rhinosinusitis.


Writing for Science, Derek Lowe spotlights how MIT researchers are developing a platform that could be used to automate the production of molecules for use in medicine, solar energy and more. “The eventual hope is to unite the software and the hardware in this area,” reports Lowe, “and come up with a system that can produce new compounds with a minimum of human intervention.”

CBC News

MIT researchers have found that some inactive ingredients in medications could play a role in triggering irritation or allergic reactions, reports Bob McDonald for CBC Radio. The researchers hope that, “pharmaceutical companies provide more information to doctors, and that alternative drug formulas can be developed for people with allergies or sensitivities.”


Prof. Giovanni Traverso speaks with STAT reporter Shraddha Chakradhar about a study examining how the inactive substances in most medications could trigger a patient’s allergies and intolerances. “As you start taking more and more tablets, then you are also taking more and more of some of these ingredients,” says Traverso. “We want to raise awareness that these ingredients are there.”

NBC News

NBC News reporter Linda Caroll writes about a new study by MIT researchers showing that inactive ingredients in medications could lead to adverse reactions in some patients. The researchers found that some of the inactive ingredients “can worsen symptoms in people with conditions such as irritable bowel syndrome, or IBS.”


Gizmodo reporter Ed Cara writes about a study by MIT researchers have finds “inactive” ingredients in pills could trigger a patient’s allergies or intolerances. “We’re not saying that everyone should stop taking these medications,” explains Prof. Giovanni Traverso. “But people with an allergy or intolerance should definitely have the opportunity to find out if they have to worry about certain medications.”


MIT researchers have found that many pills contain “inactive” ingredients that could be troublesome for patients, reports Richard Harris for NPR. Prof. Giovanni Traverso explains that if a patient with lactose intolerance takes a pill containing lactose, “it's probably not going to manifest in any significant symptoms. But as the number of pills you're taking [increases], then certainly you might cross that threshold."

Associated Press

AP reporter Lauran Neergaard writes that a new study by MIT researchers finds that pills often contain “inactive” ingredients capable of causing allergic or gastrointestinal reactions. The researchers found that “it’s hard for those patients, or even their doctors, to tell if a pill contains an extra ingredient they should avoid,” Neergaard explains.


A team of researchers led by Prof. J. Christopher Love has developed a system to produce on-demand clinical-grade vaccines and drugs, writes Dr. Francis Collins on the NIH Director’s Blog. In addition to allowing on site production for hospitals the systems could also “produce biologic treatments specially tailored to attack the cancer of a particular individual,” suggests Collins.


Writing for STAT, Karen Weintraub spotlights Prof. J. Christopher Love’s work developing a new desktop drug manufacturing process that can produce thousands of doses of biopharmaceuticals on demand. “I think in the long run there’ll be an opportunity to think about manufacturing for patients in a new way,” says Love.

The Boston Globe

Alumni Keith Dionne and Frank Gentile, who met as graduate students in 1983, have launched a biotech company based on how cells detoxify and repair themselves, reports Jonathan Saltzman of The Boston Globe. Saltzman explains that by creating drugs to induce a process called autophagy, Dionne and Gentile hope to “help cells rid themselves of debris associated with diseases” like Alzheimer’s and Parkinson’s.